secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK:        0001314052
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001731122-26-000678
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anavex terminates CEO Christopher Missling for cause; appoints Terrie Kellmeyer as interim CEO
--------------------------------------------------------------------------------

- Christopher Missling terminated as CEO for cause effective April 30, 2026; Board requested his resignation.
- Terrie Kellmeyer appointed Interim CEO effective May 4, 2026; former SVP Clinical Development at Anavex.
- Kellmeyer's compensation: $500k base salary, 30% bonus, $150k signing bonus, 200k stock options pending.
- Company expects to file Form 12b-25 to extend deadline for Q2 2026 10-Q (quarter ended March 31, 2026).
- Conference call to discuss Q2 2026 financial results and filing to be scheduled later.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314052/000173112226000678/0001731122-26-000678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314052/000173112226000678/e7613_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-26-000678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer